[ad_1]
Torrent Prescribed drugs Ltd goals to be within the first wave of generic launches of Novo Nordisk’s weight-loss medication Wegovy and Ozempic in Brazil beginning subsequent 12 months, the corporate’s administration stated on Monday, with out sharing actual timelines.
Semaglutide, the GLP-1 (glucagon-like peptide-1) compound which is bought beneath model names Wegovy and Ozempic, is ready to go off patent in key markets, together with India and Brazil, in March 2026. Indian generic gamers are gearing as much as money in on the blockbuster alternative.
Whereas declining to share the corporate’s particular plans, Sanjay Gupta, Torrent Pharma’s head of worldwide enterprise, instructed traders in a post-earnings name that the Ahmedabad-based drugmaker is planning generic launches for each Ozempic and Wegovy in Brazil.
“…we’re engaged on each the merchandise with out providing you with extra specificities. And we try to be within the wave-one of launches,” Gupta stated, including that the corporate is working with companions for each the medication.
In Brazil, Ozempic’s market dimension has declined since 2024 following the launch of Wegovy, stated Gupta. “The present dimension of Ozempic has come down rather a lot…by the point it goes off-patent, it will be smaller,” he stated, including that resulting from adjustments in rules, it’s shedding share to Wegovy.
“Wegovy ought to come to the market a little bit later as a result of individuals haven’t began submitting but…I might be way more gung-ho about Wegovy due to the place the market goes and the truth that we’ve higher possibilities of being on day one,” he stated.
As of 2024, Brazil’s Semaglutide market was estimated at $581 million. The worldwide market dimension for GLP-1 is predicted to develop to $100 billion by 2030, based on Goldman Sachs, a financial institution.
India, Brazil drive development
Torrent Pharma reported a 20% year-on-year enhance in web revenue within the June quarter to ₹548 crore, on the again of double-digit development in its largest branded markets, India and Brazil.
The corporate’s income rose 11% year-on-year to ₹3,178 crore within the June quarter, in step with estimates. Its Ebitda (earnings earlier than curiosity, taxes, depreciation, and amortisation) elevated 14% to ₹1,032 crore, with an working Ebitda margin of 32.5%.
The corporate’s administration expects the margin to stay steady by means of FY26.
Its India enterprise grew 11% YoY to ₹1,811 crore, led by outperformance in key therapies.
Additionally Learn: Cipla sees weight-loss medication as the most important alternative in India
“We anticipate the India enterprise to proceed outperforming the market development. Our focus throughout the 12 months will probably be to proceed to enhance the market share in focus therapies, new launch efficiency, enhance teamforce productiveness in expanded divisions and areas and proceed the investments and scale-up of the patron well being portfolios,” Aman Mehta, managing director-designate, instructed traders.
Mehta is ready to take the function of managing director at Torrent Prescribed drugs beginning 1 August. He has been concerned primarily with Torrent Pharma’s India enterprise, the corporate’s largest income contributor, and has performed an instrumental function within the integration of Unichem Laboratories Ltd, acquired in 2017, and the acquistion of Curatio Healthcare Pvt. Ltd. in 2022.
The corporate’s Brazil enterprise noticed its revenues rise 11% to ₹218 crore.
JB Pharma acquisition to spice up India play
Torrent is presently within the technique of buying a controlling stake in drugmaker JB Chemical compounds and Prescribed drugs (JB Pharma) from international funding agency KKR. The deal, introduced in late June, values JB Chemical compounds at an fairness valuation of ₹25,689 crore. The deal will probably be adopted by a merger of the 2 entities.
The deal will strengthen Torrent’s presence within the Indian market, catapulting it to the fifth-largest pharma firm within the nation, from seventh place. It can additionally facilitate its entry into the fast-growing contract improvement and manufacturing (CDMO) section.
The corporate is presently awaiting a call from the Competitors Fee of India (CCI) on the deal, the administration stated.
[ad_2]
Supply hyperlink